Procedure for preparing salmon calcitonin
The present invention relates to a procedure for the preparation of salmon calcitonin and all of its pharmaceutically acceptable salts formed by acid addition or complexes thereof. The invention further relates to the preparation of intermediate compounds which are useful in the synthesis of salmon calcitonin according to the invention. 
     BACKGROUND OF THE INVENTION 
     Salmon calcitonin is a natural peptide hormone extracted from said animal and which is 40 times more active than human calcitonin, a hormone with an essentially similar structure secreted mainly by the parafollicular cells of the thyroid in order to regulate the level and distribution of intra and extracellular calcium. Both human and salmon calcitonin have therapeutic applications in the prevention of senile and post menopause osteoporosis, as well for patients suffering from Paget&#39;s disease. 
     Many ways of obtaining calcitonins (human, salmon, eel, porcine, etc.) have been described in the past, for example by extracting tissue from the-various species, by DNA recombination techniques and by chemical synthesis. 
     Thus, salmon calcitonin can be obtained by extraction from the bronchial glands of said animal. Nevertheless, the low yield of active extract produced by this process has lead to the search for means ,of synthesizing it as an alternative to extraction. 
     Among the methods of obtaining calcitonin by chemical synthesis, and in parallel with the advances in the synthesis of peptides and proteins, chemical methodologies in solution and in the solid phase have been described. 
     The synthesis of salmon calcitonin by means of a classical strategy of peptide synthesis was described in 1969 by Guttman Set el. al. (HELV.; Chim. Acta52, 1789-1795). The innovation of solid ,phase synthesis processes in the field of peptide synthesis, the introduction of new orthogonal combinations of protective groups and new supports, together with the strategy of convergent synthesis, have opened up new possibilities in the procedures for obtaining calcitonin. 
     Until now various solid phase synthesis procedures for obtaining calcitonin (human, porcine, bovine, salmon, eel, etc.) have been mentioned in the U.S. Pat. Nos. 3,926,938 and 3,891,614 as well as in the articles by Kamber. B, Riniker. B, Peptides: Chemistry and Biology, pp. 525-6 (Smith J. A., Rivier J. E. Eds) 1992 ESCOM Science Publishers, basically using Boc/Bzl type protection strategies (Barney G., Merrifield R. B., (1980) The Peptides (Gross E., Melenhofer J. Eds) vol. 2 pp 1-284, Academic Press, New York), both in convergent synthesis schemes (Pedroso et al. Tetrahedron (1982), 38, 1183) (the Joining of two or more fragments) and in linear synthesis processes (the Joining of the 32 amino acids one by one). In general the use of Boc/Bzl derivatives implies a high yield cost both in the processes of synthesis related to the strong deprotection conditions, and consequently the elaborate purification processes. 
    
    
     DESCRIPTION OF THE INVENTION 
     The present invention is based on investigations into the solid phase synthesis of calcitonin using the methodology known as soft conditions, based on the use of Fmoc/t-Bu type protection which requires softer deprotection conditions, either with linear or convergent synthesis protocols, i.e. by the condensation of complementary fragments in solution or in the solid phase. 
     Some examples of solid phase synthesis with Fmoc/t-Bu type protection can be found in recent literature. 
     Surprisingly it has now been found that, after the liberation/deprotection of the complete peptide skeleton, the strategy of convergent synthesis by means of the condensation of Fragments 1 and 2 or 3 (SEQ ID NOS: 1 and 2 or 3) (Diagrams 1 and 2 below) leads to a reaction crude with a high yield of calcitonin, which means that not only is the purification process simplified but the yields of other processes described are increased. 
     The present invention therefore provides a new procedure for solid phase synthesis with new polymeric supports and a new synthesis methodology using protective groups combined with the convergent strategy. 
     In particular, the present invention provides a procedure for obtaining salmon calcitonin, a peptide hormone comprising 32 sequential amino acids, based on solid phase synthesis using Fmoc/t-Bu type protective group methodology (on convenient functionalized supports) combined with a convergent strategy, all according to the following diagram: ##STR2## 
     As shown, R refers to the R of diagram 1, namely the solid support and the bridge groups having the structure shown after the colon. 
     Referring to the previous diagram 1, the procedure of the invention consists of the condensation of fragment 1, (SEQ ID NO:1) a docosapeptide corresponding to the carboxamide end of the salmon calcitonin sequence, conveniently protected and anchored on resin, with fragment 2(SEQ ID NO:2), a decapeptide corresponding to the amino end of the salmon calcitonin sequence, conveniently protected and with a disulphide bridge ready formed between the two cysteines. 
     Once the complete peptide skeleton (fragment 6(SEQ ID NO:6) has been constructed the peptide is cleaved from the resin and totally deprotected, already in its oxide form, by means of an acid treatment. Finally, after subsequent purification chemically pure salmon calcitonin is obtained. 
     In particular, the condensation of fragment 1 with fragment 2 (diagram 1(SEQ ID NO:2)) which leads to fragment 6 (SEQ ID NO:6) (not described previously by literature) is carried out by the conventional methods of solid phase synthesis which have already been described. Once condensation is complete, the peptide-resin is subjected to a simultaneous process of deprotection of the side chains and de-anchoring the resin using 95% trifluoroacetic acid in the presence of scavengers. The resulting crude is purified by high pressure liquid chromatography. All of the homogeneous fractions are combined and are freeze-dried, thereby obtaining chemically pure salmon calcitonin. 
     According to another modality, the procedure of the invention may be carried out according to the following diagram 2: ##STR3## where R is defined as before in diagram 1 and structure of R shown immediately after diagram 1 wherein R is an abbreviation for the solid support and bridge groups. 
     According to diagram 2, fragment 1 (SEQ ID NO:1) is condensed with fragment 3(SEQ ID NO: 2) , the precursor of fragment 2(SEQ ID NO:2), and then the disulphide bride is formed between the two cysteines (fragment 7(SEQ ID NO: 7)) by a solid phase selective oxidation reaction. Finally, once the peptide structure is complete in its oxidized form (fragment 6(SEQ ID NO: 6)) (with the disulphide bridge between the two cysteines) the deprotection of the remaining protective groups and liberation from the resin is carried out. After conventional purification, chemically pure salmon calcitonin is thus obtained. 
     According to another aspect and as mentioned above, the invent:ion also provides a procedure for obtaining said fragment 1(SEQ ID NO:1), as well as a procedure for obtaining fragment 2(SEQ ID NO:2) and its precursor fragment 3(SEQ ID NO:3) and other fragments, all of them used in diagrams 1 and 2 above for the preparation of salmon calcitonin according to the present invention. 
     Fragments 1 and 2 (SEQ ID NO:2) are obtained starting with paramethylbenzhydrilamine resin (pMBHA) and incorporating an internal standard and a bridge group (handle) between the resin and the amino acids of the respective sequences. 
     To obtain fragment 1(SEQ ID NO:1), and because the terminal carboxy end of salmon calcitonin is a carboxamide, the bridge group or handle which is incorporated is [1-(9H-fluoren-9-yl)methoxy-formamide]methyl-3,5-dimethoxyphenoxyvaleric acid (Fmoc-PAL) (Albericio et al. J.Org. Chem. (1990), 55, 3730) or alternatively p-[(R,S)-a-[1-(9H-fluoren-9-yl)methoxy -formamide]-2,4-dimethoxy benzyl]-phenoxy acetic acid (Fmoc-AM) (Atherton et al. J. Am. Chem. Soc, (1975), 97,6584. The incorporation of the bridge group is followed by linear synthesis, residuum by residuum, until the 22 amino acids have been incorporated, using Fmoc as the protective group for the amino end in all cases. For the side chains Lys, Ser, Thr, Tyr, Arg, Glu, His, Gln and Asn, the protective groups are those indicated in the following FIG. 3: ##STR4## where R is defined as before in diagram 1 and the structure of -R shown immediately after diagram 1. 
     To obtain fragment 2(SEQ ID NO:2), and because the terminal carboxy end must be carboxyacid, the bridge group or handle incorporated is 4(4-hydroxymethyl-3-methoxyphenoxy)butyric acid known as the Riniker Handle (}IMP.B) (Florsheimer et al.). The incorporation of bridge group is followed by linear synthesis, residuum by residuum, until the ten amino acids have been incorporated, using Fmoc as the protective group for the amino end in all cases except the last amino acid, for which the Boc group is used. For the protection of the side chains Ser, Thr, Asn, Cys the groups tBU, Trt or Acm are used respectively obtaining fragment 4(SEQ ID NO:4), not previously described by literature, as indicated in the following diagram 4: ##STR5## 
     The simultaneous deprotection/oxidation with iodine of the two protective groups of the cysteine residua (Acm and Trt) respectively, leads to fragment 5(SEQ ID NO:5), not previously described in literature, with a high yield and a high degree of purity. Finally, by breaking the peptide-resin bond with trifluoroacetic acid in 1% dichloromethane, fragment 2 (SEQ ID NO:2) is produced. 
     Alternatively, referring again to diagram 4, by breaking the peptide-resin link of fragment 4(SEQ ID NO:4) fragment 3(SEQ ID NO:3) is obtained, a product not previously described by literature and which, by oxidation with iodine, can in turn lead to fragment 2(SEQ ID NO:2). 
     The abbreviations used in the present description have the following meanings: 
     Acm: acetamidomethyl 
     AcOH: acetic acid 
     AM: p-[(R,S)-2,4-dimethoxy benzyl]-phenoxy acetic 
     Arg: L-arginine 
     Asn: L-asparagine 
     Boc: t-butoxycarbonyl 
     Bzl: benzyl 
     Cis: cystine 
     Cys: cysteine 
     DCM: dichloromethane 
     DMF: N,N&#39;-dimethylformamide 
     DIEA: N,N&#39;-diisopropylethyl amine 
     DIPCDI: diiosopropylcarbodiimide 
     DMAP: dimethylamtnopyridine 
     Fmoc: 9-fluorenylmethoxycarbonyl 
     Gln: L-glutamine 
     Glu: L-glutamic acid 
     Gly: L-glycine 
     HBTU : O -(benzotriazole-1-yl)-N,N,N&#39;,N&#39;-tetramethyluronide hexafluorophosphate 
     His: L-histidine 
     HMPB: 4(4-hydroxymethyl-3-methoxyphenoxy)butyric acid 
     HOBT: N-hydroxybenzotriazole 
     HPLC: high pressure liquid chromatography 
     Leu: L-leucine 
     Lys: L-lysine 
     Meb: p-methylbenzyl 
     Mtr: methoxytrityl 
     MPLC: medium pressure liquid chromatography 
     PAL: aminomethyl-3,5-dimethoxyphenoxyvaleric acid 
     pMBHA: para-methylbenzhydrilamine 
     Pmc: 2,2,5,7,8-pentamethylchroman-6-sulphonyl 
     Pro: L-proline 
     Ser: L-serine 
     tBu: tert-butyl 
     TFA: trifluoroacetic acid 
     TFMSA: trifluoromethanesulphonic acid 
     Thr: L-threonine 
     Tos: tosyl 
     Trt: trityl 
     Tyr: L-tyrosine 
     The invention is illustrated below by means of the following non-limiting examples. 
     EXAMPLE 1 
     Incorporation of an internal standard. Obtaining BocIle-pMBHa. 
     1.658 g (6.9 mmoles) of BocIle are incorporated on 4 g of p-methylbenzhydrilamine resin of 0.69 mmoles/g resin as an internal standard by means of the synthesis programme described below: 
     
         ______________________________________                                    
Step      Reagent      Repetitions                                        
                                 Time                                     
______________________________________                                    
1         TFA 40%      1         2&#39;                                       
2         TFA 40%      1         20&#39;                                      
3         DCM          5         1&#39;                                       
4         DIEA 5%      3         2&#39;                                       
5         DCM          5         1&#39;                                       
6         Boc aa       -         +                                        
7         HOBt         -         +                                        
8         DIPCDI       -         40&#39;                                      
9         DCM          5         1&#39;                                       
10        check with ninhydrin, if + return to 6,                         
          if - continue                                                   
11        DCM          5         1&#39;                                       
12        TFA 40%      1         2&#39;                                       
13        TFA 40%      1         20&#39;                                      
14        DCM          5         1&#39;                                       
15        DIEA 5%      3         2&#39;                                       
16        DCM          5         1&#39;                                       
______________________________________                                    
 
    
     EXAMPLE 2 
     Incorporation of the Riniker handle. Obtaining 4(4-hydroxymethyl-3-methoxyphenoxy)butyramide-Ile-pMBHA. 
     There then follows the incorporation of 4(4-hydroxymethyl-3-methoxyphenoxy)butyric acid, also known as the Riniker handle (HMPB). This is carried out by reacting 4 g of the resin (fNH 2  0.69 mmoles/g of resin), after it has been previously functionalized with the internal standard, with 1 g (4.14 Moles of, 1.5 equivalents) of 4(4-hydroxymethyl-3-methoxyphenoxy) butyric acid, 0.62 g (4.14 mmoles, 1.5 equivalents) of HOBt and 641 μl (4.14 mmoles, 1.5 equivalents) using DMF as the solvent. The reaction time is 90&#39;. After this time has elapsed, the resin is washed five times with DCM and the Kaiser is used to check that there are no free amines. If there are, the coupling process must be repeated. 
     EXAMPLE 3 
     Incorporation of the first amino acid. Obtaining Fmoc Gly-Riniker handle-Ile-pMBHA. Riniker handle-Ile-pMBHA. 
     The incorporation of the first amino acid, in this case glycine, implies the formation of an ester-type link between the handle and the Fmoc Gly derivative. For this kind of incorporation the resin is reacted with 4.1 g (5 equivalents) of Fmoc Gly in the presence of 168 mg (0.5 equivalents) of DMAP and 2.094 ml (5 equivalents) of DIPCDI in DMF for 90&#34;. Once the reaction is complete the resin is washed five times with DMF. An amino acid analysis of an acid hydrolysis of the resin .gives the ratio of the Ile amino acid (internal standard) and the first amino acid Gly. In this way the real functionalization of the resin is known, normally varying between 0.35-0.69 mmoles/g. 
     EXAMPLE 4 
     Incorporation of the remaining amino acids. Obtaining BocCys(Acm)-Ser(tBu)-Asn-Leu-Ser(tBu)-Thr(tBu)-Cys(Trt)-Val-Leu-Gly-Riniker handle-Ile-pMBHA (fragment 4). 
     The incorporation of the remaining amino acids is carried out by following a synthesis programme such as the one described below: 
     
         ______________________________________                                    
Step     Reagent        Repetitions                                       
                                  Time                                    
______________________________________                                    
1        DMF            5         1&#39;                                      
2        pip/DMF 20%    1         1&#39;                                      
3        pip/DMF 20%    1         5&#39;                                      
4        DMF            5         1&#39;                                      
5        Fmoc aa        --        +                                       
6        HOBt           --        +                                       
7        DIPCDI         --        40&#39;                                     
8        DMF            5         1&#39;                                      
______________________________________                                    
 
    
     check with ninhydrin, if+return to 5, if--continue with step 1 and the next amino acid. 
     In order to evaluate the synthetic purity of the totally deprotected peptide 1-10, 20 mg of BocCys(Acm) -Ser(tBu)-Asn-Leu-Ser(tBu)-Thr(tBu)-Cys(Trt)-Val-Leu-Gly -Riniker handle-Ile-pMBHA are treated with 900 μl of TFA, 50 μl of thioanisole, 30 μl of EDT and 20 μl of anisole for 2 hours at room temperature in a reactor provided with a filter plate. The filtrate is collected in a tube with cold, dry diethyl ether. The precipitation of the free peptide is observed and after centrifuging the floating material is decanted. The pellet is resuspended once again in cold, dry ether to eliminate the scavengers (EDT, thioanisole, anisole). This operation is repeated five times. Afterwards the pellet is dried and then dissolved in 1 ml of 10% acetic acid solution. 40 μl of the peptide solution are injected into HPLC with a gradient of 5-85% B, where A: H 2  O 0.045% TFA and B: CH 3  CN 0.035% TFA, Vydac C18 5 μm, 25×0.46 cm. An amino acid analysis of a hydrolysis of the peptide-resin at 150° C. for 3 hours with a mixture of HCl/propanoic acid gives the following composition Asp 1.01 (1), Thr 0.8 (1), Ser 1.6 (2), Gly 1.2 (1), Ile 1.5-1 (1), Leu 1.99 (2), Val 0.89 (1). 
     EXAMPLE 5 
     Breaking the peptide 1-10 from the resin. Obtaining ##STR6## 
     This treatment can be carried out either before or after the oxidation process, as indicated in diagram 4. The subsequent treatment differs slightly in each case. In order to break the peptide-resin link before oxidation, route A must be followed. To break the link after oxidation route B must be followed. 
     Route A: The peptide-resin is treated with 1% TFA in DCM 4 or 5 times at intervals of 15 minutes, hexane is added to the filtrates and it is evaporated in a rotavapour. A white solid is obtained. 
     Route B: The peptide-resin is treated with 1% TFA in DCM 4  or 5 times at intervals of 15 minutes. After each filtration the ,solution is neutralised with twice as much pyridine as the amount of TFA which the solution contains. The total of the filtrates is concentrated to 20% of its initial volume in the rotavapour. The concentrated peptide solution is added to cold diethyl ether. The white precipitate obtained is separated by centrifuging. The solid is resuspended in diethyl ether and centrifuged once again. This operation is repeated three more times. Finally the solid obtained is dried. 
     EXAMPLE 6 
     Formation of disulphide bridge on resin. Obtaining ##STR7## 
     The deprotection and simultaneous formation of disulphide bridge links on the resin BocCys(Acm) Ser(tBu) -Asn-Leu-Ser(tBu)-Thr(tBu)-Cys(Trt)-Val-Leu-Gly-handle-(R) is carried out in DCM/MeOH/H 2  O (6:2.5:0.42) with two I 2  equivalents over two intervals of 30 minutes. 
     EXAMPLE 7 
     Formation of disulphide bridge in solution. Obtaining ##STR8## 
     The oxidization of the peptide Boc Cys(Acm)-Ser(tBu) -Asn-Leu-Ser(tBu)-Thr(tBu)-Cys(Trt)-Val-Leu-Oly-OH is carried out in DCM/MeOH/H 2  O (6:2.5:0.42) with 4 I 2  equivalents for 10 minutes. Afterwards the reaction mixture is washed with a solution of sodium thiosulphate 0.1N adding CHCl 3 . The organic phase is washed with water, dried with sodium sulphate and evaporated to dryness. A white solid is obtained. 
     EXAMPLE 8 
     Incorporation of the Fmoc AM handle on Boc-Ile-pMBHa. Obtaining p-[(R,S)-a-[1-(9H-fluoren-9-yl)methoxy-formamide]-2,4-dimethoxy benzyl]-phenoxy acetamide-Ile pMBHA. 
     There then follows the incorporation of p-[(R,S)-a-[1(9H-fluoren-9-yl)methoxy-formamide]-2,4-dimethoxy benzyl]-phenoxy acetic acid (Fmoc-AM). This is carried out by reacting 4 g of the resin (0.69 mmoles/g of resin), after it has been previously functionalized with the internal standard (following the protocol described in example 1), with 2.23 g (4.14 mmoles, 1.5 equivalents) of p-phenoxy-acetic acid, 0.62 g (4.14 mmoles, 1.5 equivalents) of HOBt and 641 μl (4.14 mmoles, 1.5 equivalents) using DMF as the solvent. The reaction time is 90&#39;. After this time has elapsed, the resin is washed five times with DCM and the Kaiser test is used to check that there are no free amines. If there are, the coupling process must be repeated. 
     EXAMPLE 9 
     Incorporation ,of the Fmoc PAL handle on Boc-Ile-pMBHa. Obtaining 4[1-(9H-fluoren-9-yl)methoxy-formamide]methyl -3.5-dimethoxyphenoxyvaleriamide-Ile pMBHA. 
     There then follows the incorporation of 4[1-(9H -fluoren-9-yl)methoxy-formamide]methyl-3,5-dimethoxyphenoxyvaleric acid (Fmoc-PAL). This is carried out by reacting 4 g of the resin (0.69 mmoles/g of resin), after it has been previously functionalized with the internal standard (following the protocol described in example 1), with 1.89 g (4,14mmoles, 1.5 equivalents) of 4[1-(9H -fluoren-9-yl)methoxy-formamide]methyl-3,5-dimethoxyphenoxyvaleric acid, 0.62 g (4.14 mmoles, 1.5 equivalents) of HOBt and 641 μl (4.14 mmoles, 1.5 equivalents) using DMF as the solvent. The reaction time is 90&#39;. After this time has elapsed, the resin is washed five times with DCM and the Kaiser is used to check that there are no free amines. If there are,, the coupling process must be repeated. 
     EXAMPLE 10 
     Incorporation of the remaining amino acids. Obtaining Fmoc Lys(Boc)-Leu-Ser(tBu)-Gln-Glu(tBu)-Leu-His(Trt)-Lys (Boc)-Leu-Gln-Thr(tBu)-Tyr(tBu)-Pro-Arg(Pmc)-Thr(tBu)-Asn -Thr(tBu)-Gly-Ser(tBu)-Gly-Thr(tBu)-Pro-AM-Ile-PMBHA. 
     The incorporation of the remaining amino acids is carried out by following a synthesis programme such as the one described below: 
     
         ______________________________________                                    
Step     Reagent        Repetitions                                       
                                  Time                                    
______________________________________                                    
1        DMF            5         1&#39;                                      
2        pip/DMF 20%    1         1&#39;                                      
3        pip/DMF 20%    1         5&#39;                                      
4        DMF            5         1&#39;                                      
5        Fmoc aa        --        +                                       
6        HOBt           --        +                                       
7        DIPCDI         --        40&#39;                                     
8        DMF            5         1&#39;                                      
______________________________________                                    
 
    
     check with ninhydrin, if+return to 5, if-continue with step 1 and the next amino acid. 
     In order to evaluate the synthetic purity of the totally deprotected peptide 11-32, 20 mg of Fmoc Lys(Boc) -Leu-Ser(tBu)-Gln-Glu(tBu)-Leu-His(Trt)-Lys(Boc)-Leu-Gln -Thr(tBu)-Pro-Arg(Pmc)-Thr(tBu)-Gly-Ser(tBu)-Gly-Thr(tBu) -Pro-AM-Ile-pMBHA (fragment 1 are treated with 900 μl of TFA, 50 μl of thioanisole, 30 μl of EDT and 20 μl of anisole for 2 hours at room temperature in a reactor provided with a filter plate. The filtrate is collected in a tube with cold, dry diethyl ether. The precipitation of the free peptide is observed and after centrifuging the floating material is decanted. The pellet is resuspended once again in cold, dry ether to eliminate the scavengers (EDT, thioanisole, anisole). This operation is repeated five times. Afterwards the pellet is dried and then dissolved in 1 ml of a solution of 10% acetic acid. 40 μl of the peptide solution are injected into HPLC with a gradient of 5-85% B, where A: H 2  O 0.045% TFA and B: CH CN 0.035% TFA, Vydac C 18 5 μm, 25×0.46 cm. An amino acid analysis of a hydrolysis of the peptide-resin at 150° C. for 3 hours with a mixture of HCl/propanoic acid gives the following composition Asp 1.06 (1), Thr 4.0 (4), Ser 2.0 (2), Glu 3.01 (3), Gly 2.2 (2), Pro 1.98 (2), Ile 0.9 (1), Leu 3.0 (3), Tyr 0.8 (1), His 0.92 (1), Lys 1.8 (2), Arg 1.03 (1). 
     EXAMPLE 11 
     Incorporation of fragment 2 on the peptide-resin of fragment 1. Obtaining Boc Cis-Ser(tBu)-Asn-Leu-Ser(tBu) -Thr(tBu)-Cis-Val-Leu-Gly-Lys(Boc)-Leu-Ser(tBu)-Gln -Glu(tBu)-Leu-His(Trt)-Lys(Boc)-Leu-Gln-Thr(tBu)-Tyr(tBu) -Pro-Arg(Pmc)-Thr(tBu)-Asn-Thr(tBu)-Gly-Ser(tBu)-Gly -Thr(tBu)-Pro-AM-Ile-pMBHA (fragment 6). 
     1.58 g of the peptide-resin 11-32 are treated with piperidine/DMF for 3 minutes. The operation is repeated two more times and the resin is then washed 5 times for 1 minute with DMF. 315 mg (2.5 equivalents) of HBTU and 124 mg (2.5 equivalents) of HOBT dissolved in DMF are added to the resin, forming the most homogeneous mass possible therewith. 1.05 g (2.5 equivalents) of the peptide 1-10, its N-terminal end and side chains being totally protected by the disulphide bridge already formed, is dissolved in the minimum quantity possible of DMF and added to the resin. Finally 296 μl (5 equivalents) of DIEA are added. The resin is shaken well until it is homogeneous. The reaction acquires an orange colour. One hour and 30 minutes later the Kaiser test on one aliquot, part of the resin gives a negative result and the incorporation reaction can be considered complete. The resin is filtered and washed repeatedly with DMF. 
     EXAMPLE 12 
     Breaking the resin and deprotection of the peptide 1-32. Obtaining ##STR9## when completely dry is treated with TFA/DCM/anisole (95:3:2) for 2 hours at room temperature. Afterwards the filtrate is poured onto 100 ml of cold, dry diethyl ether. The white precipitate obtained is separated by centrifuging. The solid is resuspended In diethyl ether and centrifuged again. This operation is carried out five more times. Finally the solid obtained is dried. The solid dissolved in 10% AcOH is purified by an HPLC preparation with a gradient of 5-65% B, where A: H 2  O 0.05% TFA and B: CH 3  CN 0.05% TFA, Vydac C 18 15-20 μm, 25×1 cm. 
     
         __________________________________________________________________________
SEQUENCE LISTING                                                          
(1) GENERAL INFORMATION:                                                  
(iii) NUMBER OF SEQUENCES: 7                                              
(2) INFORMATION FOR SEQ ID NO:1:                                          
(i) SEQUENCE CHARACTERISTICS:                                             
(A) LENGTH:22 amino acids                                                 
(B) TYPE:amino acid                                                       
(C) TOPOLOGY:linear                                                       
(ii) MOLECULE TYPE:protein                                                
(v) FRAGMENT TYPE:C-Terminal type                                         
(ix) FEATURE:                                                             
 (D) OTHER INFORMATION:Lys position 1 substituted with                    
6 t- butoxycarbonyl                                                       
Ser at position 3 substituted with                                        
tert- butyl                                                               
Glu at position 5 substituted with                                        
tert- butyl                                                               
His at position 7 substituted with                                        
trityl                                                                    
Lys at position 8 substituted with                                        
 t- butoxycarbonyl                                                        
Thr at position 11 substituted with                                       
tert- butyl                                                               
Tyr at position 12 substituted with                                       
tert- butyl                                                               
Arg at position 14 substituted with                                       
2,2,5,7,8- pentamethylchroman-6-sulphonyl                                 
Thr at position 15 substituted with                                       
tert- butyl                                                               
 Thr at position 17 substituted with                                      
tert- butyl                                                               
Ser at position 19 substituted with                                       
tert- butyl                                                               
Thr at position 21 substituted with                                       
tert- butyl                                                               
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:                                   
LysLeuSerGlnGluLeuHisLysLeuGlnThrTyrProArgThrAsn                          
151015                                                                    
ThrGlySerGlyThrPro                                                        
20                                                                        
(2) INFORMATION FOR SEQ ID NO:2:                                          
(i) SEQUENCE CHARACTERISTICS:                                             
(A) LENGTH:10 amino acids                                                 
(B) TYPE:amino acid                                                       
(D) TOPOLOGY:linear                                                       
(ii) MOLECULE TYPE:protein                                                
(v) FRAGMENT TYPE:N-terminal                                              
(ix) FEATURE:                                                             
(D) OTHER INFORMATION: Ser at position 2 substituted                      
with tert- butyl                                                          
Ser at position 5 substituted with tert-butyl                             
Thr at position 6 substituted with tert-butyl                             
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 2:                                  
CysSerAsnLeuSerThrCysValLeuGly                                            
1 510                                                                     
(2) INFORMATION FOR SEQ ID NO:3:                                          
(i) SEQUENCE CHARACTERISTICS:                                             
(A) LENGTH:10 amino acids                                                 
(B) TYPE:amino acid                                                       
(D) TOPOLOGY:linear                                                       
(ii) MOLECULE TYPE:protein                                                
(v) FRAGMENT TYPE:                                                        
(ix) FEATURE:N-Terminal                                                   
(D) OTHER INFORMATION: Cys in position 1 substituted                      
with acetamidomethyl                                                      
 Ser in position 2 substituted with                                       
tert- butyl                                                               
Thr in position 6 substituted with                                        
tert- butyl                                                               
Cys in position 7 substituted with                                        
trityl                                                                    
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:                                   
CysSerAsnLeuSerThrCysValLeuGly                                            
1 510                                                                     
(2) INFORMATION FOR SEQ ID NO:4:                                          
(i) SEQUENCE CHARACTERISTICS:                                             
(A) LENGTH:10 amino acids                                                 
(B) TYPE:amino acid                                                       
(D) TOPOLOGY:linear                                                       
(ii) MOLECULE TYPE:protein                                                
(ix) FEATURE:                                                             
(D) OTHER INFORMATION: Cys at position 1 substituted                      
with acetamidomethyl                                                      
Ser at position 2 substituted with tert-butyl                             
Ser at position 5 substituted with tert-butyl                             
Thr at position 6 substituted with tert-butyl                             
Cys at position 7 substituted with trityl                                 
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:                                   
CysSerAsnLeuSerThrCysValLeuGly                                            
1510                                                                      
(2) INFORMATION FOR SEQ ID NO:5:                                          
(i ) SEQUENCE CHARACTERISTICS:                                            
(A) LENGTH:10 amino acids                                                 
(B) TYPE:amino acid                                                       
(D) TOPOLOGY:linear                                                       
(ii) MOLECULE TYPE:protein                                                
(ix) FEATURE:                                                             
(D) OTHER INFORMATION: Ser at position 3                                  
substituted with tert-butyl                                               
Ser at position 6 substituted with tert-butyl                             
Thr at position 7 substituted with tert-butyl                             
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:                                   
Cy sSerAsnLeuSerThrCysValLeuGly                                           
1510                                                                      
(2) INFORMATION FOR SEQ ID NO:6:                                          
(i) SEQUENCE CHARACTERISTICS:                                             
(A) LENGTH:32 amino acids                                                 
(B) TYPE:amino acid                                                       
(D) TOPOLOGY:linear                                                       
(ii) MOLECULE TYPE:protein                                                
(ix) FEATURE:                                                             
 (D) OTHER INFORMATION: Ser at position 2 substituted                     
with tert- butyl                                                          
Ser at position 5 substituted with tert-butyl                             
Tyr at position 4 substituted with tert-butyl                             
Arg at position 6 substituted with tert-butyl                             
Thr at position 6 substituted with tert-butyl                             
Lys at position 11 substituted with tert-butyl                            
Ser at position 13 substituted with tert-butyl                            
Glu at position 15 substituted with tert-butyl                            
His at position 17 substituted with trityl                                
Lys at position 18 substituted with t-butoxycarbonyl                      
Thr at position 21 substituted with tert-butyl                            
Tyr at position 22 substituted with tert-butyl                            
Arg at position 24 substituted with                                       
2,2,5,7,8- pentamethylchroman-6-sulphonyl                                 
Thr at position 25 substituted with tert-butyl                            
Thr at position 27 substituted with tert-butyl                            
Ser at position 29 substituted with tert-butyl                            
Thr at position 31 substituted with tert-butyl                            
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:                                   
CysSerAsnLeuSerThrCysValLeuGlyLysLeuSerGlnGluLeu                          
151015                                                                    
 HisLysLeuGlnThrTyrProArgThrAsnThrGlySerGlyThrPro                         
202530                                                                    
(2) INFORMATION FOR SEQ ID NO:7:                                          
(i) SEQUENCE CHARACTERISTICS:                                             
(A) LENGTH:32 amino acids                                                 
(B) TYPE:amino acid                                                       
(D ) TOPOLOGY:linear                                                      
(ii) MOLECULE TYPE:protein                                                
(ix) FEATURE:                                                             
(D) OTHER INFORMATION: Ser at position 5 substituted                      
with tert- butyl                                                          
Thr at position 6 substituted with tert-butyl                             
Cys at position 7 substituted with trityl                                 
Lys at position 11 substituted with t-butoxycarbonyl                      
Ser at position 13 substituted with tert-butyl                            
Glu at position 15 substituted with tert-butyl                            
 His at position 17 substituted with trityl                               
Lys at position 18 substituted with trityl                                
Thr at position 21 substituted with tert-butyl                            
Tyr at position 22 substituted with tert-butyl                            
Arg at position 24 substituted with                                       
2,2,5,7,8- pentamethylcroman-6-sulphonyl                                  
Thr at position 25 substituted with tert-butyl                            
Thr at position 27 substituted with tert-butyl                            
 Ser at position 29 substituted with tert-butyl                           
Thr at position 31 substituted with tert-butyl                            
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:                                   
CysSerAsnLeuSerThrCysValLeuGlyLysLeuSerGlnGlu                             
151015                                                                    
LeuHisLys LeuGlnThrTyrProArgThrAsnThrGlySerGly                            
202530                                                                    
ThrPro                                                                    
__________________________________________________________________________